Compare Nu Holdings Ltd (NU) vs Summit Therapeutics Inc (SMMT) Price & Performance

NU stock trades at $13.86, up 0.14% today, with a bullish technical signal despite recent earnings misses. Revenue grew from $3.0B in 2022 to $10.6B in 2025, with net income turning positive to $2.9B. The company's expansion in Brazil and Mexico, including a pending banking license acquisition (PYMNTS, 2026-07-22), supports growth. Analysts maintain a buy consensus with a $14.98 target, though competition and Latin American market risks persist.

Outlook remains positive due to strong fundamentals and growth trajectory, but investors face risks from rising competition and regional volatility. The upcoming Q2 2026 earnings report on August 13 (Defense World, 2026-08-12) serves as a key catalyst, with expectations of $0.1984 EPS. Institutional activity is mixed, with some trimming stakes while others increase holdings.

Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.

The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.